AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
BG
ACCE-researched

Bunge Limited Common Shares (BG) fair value

Consumer Defensive · Farm Products · NYSE · United States
$103.22+0.07%
Market cap $19.8BNext earnings 2026-10-29Updated Oct 21, 2026
Add earnings to calendarGoogle
Our verdict
Trades 17% below our fair value
Price
$103.22
Model fair valueConfidence: good
$125
Model range
$95.50 to $176
Fair value $125
Price $103
3 models fit Bunge Limited Common Shares and they disagree: 0 of 3 land within 15% of the average.
Two or more of our models back this value.
Discount(i)
Valued as a mature, profitable company: Discounted cash flow, P/E comparison, EV/EBITDA comparison, and Graham number.
ACCE opinionBunge Limited Common Shares (BG)
Fair value (3 models)
$125
ACCE price target
$111
Rating
Undervalued
Horizon
12 months
Fair value published on 12 Oct 2026, 00:00 CEST; previously $122 since 8 Oct 2026, 00:00 CEST.
ACCE price target published on 18 Oct 2026, 00:00 CEST; previously $127 since 14 May 2026, 00:00 CEST.
Rating published on 21 Oct 2026, 12:04 CEST.
Price used: $103 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow, EV/EBITDA comparison, Graham number, and P/E comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
17.1% below
+20.7% to fair value
ACCE score
57
out of 100
Analysts
89% buy
9 covering
P/E
20.5x
forward 9.6x
1-year return
+6.8%
Dividend yield
2.78%

Bunge Limited Common Shares in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

Bunge is one of the largest oilseed processors and agribusiness merchants in the world, crushing soybeans and canola into vegetable oil and meal and moving grain and oilseeds across its global origination and export network. The moat is physical scale: a few dozen crush plants, port terminals and a logistics footprint that is expensive to replicate, which lets it capture processing spreads and handle volatile input costs better than smaller crushers. The 88.3% revenue growth figure is almost certainly driven by commodity price pass-through and acquisitions rather than volume, so it should be read with caution, since the 4.9% gross margin and 4.6% operating margin show how thin the business economics are. The forward P/E of 9.6, against a trailing 21.3, implies the market expects earnings to recover sharply, and that recovery is the question a deeper look needs to answer: whether crush margins and merchandising earnings normalize upward, and whether the 7.2% ROE improves from here. At a 60/100 score and no index membership, this is a cyclical, low-margin agribusiness trading on a depressed forward earnings multiple, worth a closer look only if you have a view on oilseed crush spreads and the global grain cycle.

AI-assisted·How I use AIWritten Oct 18, 2026
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
  • high
    Severe negative free cash flow
    FCF of -$6.5B despite $88% revenue growth and positive earnings signals working capital strain or capital intensity mismatch. Unsustainable at current scale.
  • high
    Quality score collapse
    ACCE Quality score 35/100 is critically weak. Combined with Momentum 39/100, suggests operational or earnings quality deterioration masking by top-line growth.
  • moderate
    Sequential revenue deceleration
    QoQ revenue -8.0% after +88.3% YoY indicates sharp slowdown. Forward P/E 9.1 may not hold if growth momentum breaks further.

AI research notes

AI-assisted·How I use AIWritten Oct 11, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
  • Revenue surged 88.3% year over year, suggesting strong demand recovery or successful market expansion.
Why it could disappoint
  • Free cash flow of negative $6.5B and negative 32.8% free cash flow yield raise serious liquidity concerns.
  • Net margin of 1.1% and ROIC of 2.2% show the business generates minimal profit on capital deployed.
  • Share count jumped 17.2% in one year while debt to equity stands at 0.98, diluting existing shareholders.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.

Next results

Oct 29, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where BG's valuation models land
Price
$103.22
Model fair value
$125
Model range
$95.50 to $176
Fair value $125
Price $103
The price sits inside the model range.
Model
Fair value
Upside
Discounted cash flow
EV/EBITDA comparison
Graham number
P/E comparison
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

Bullish89% buy · 9 covering analysts
● Strong buy 5● Buy 3● Hold 1● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Press releases mentioning this company

Recent performance

1 week
-2.8%
1 month
-7.4%
3 months
-15.1%
6 months
-17.4%
YTD
+15.9%
1 year
+6.8%

SEC filings

Recommendation history, last 12 months

DateTypeNewPreviousPrice
21 Oct 2026, 12:04 CESTRatingUndervaluedfirst publication$103
18 Oct 2026, 00:00 CESTACCE price target$111$127$106
12 Oct 2026, 00:00 CESTFair value$124$122$103
8 Oct 2026, 00:00 CESTFair value$122$124$107
20 Sept 2026, 00:00 CESTFair value$124$126$116
17 Sept 2026, 00:00 CESTFair value$126$130$121
15 Sept 2026, 00:00 CESTFair value$130$126$122
13 Sept 2026, 00:00 CESTFair value$126$130$122
10 Sept 2026, 00:00 CESTFair value$130$128$124
6 Sept 2026, 00:00 CESTFair value$128$130$119

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full BG page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth100Value61Quality35Momentum32Total57
Valuation
Trailing P/E
20.5x
Forward P/E
9.6x
PEG
1.71
P/B
1.44x
EV / Revenue
0.4x
Book value/sh
$83.04
Enterprise value
$37.4B
Profitability
ROE
7.2%
FCF yield
-4.44%
ROIC
2.1%
Health and risk
Debt / equity
1.00
Dividend yield
2.78%
Beta
0.72

Price

+5.5% · 1Y

Ask anything about BG

Answered from Bunge Limited Common Shares fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 67% of peers
low 11.3x20.5xhigh 50.9x
ROEbetter than 50% of peers
low 2%7%high 15%
Div yieldbetter than 67% of peers
low 0.3%2.8%high 3.8%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
BG Bunge Limited Common Shares$103.22$12517% below20.5x7.2%3557
TSN Tyson Foods Inc. Common Stock$57.07$562% above35.2x3.3%3046
MOWI.OL Mowikr 215.80kr 2122% above15.6x15.5%5963
ADM Archer-Daniels-Midland Company Common Stock$79.84$868% below21.9x7.6%4465
LOUP.PA L.D.C. S.A.€104.60€16838% below11.3x13.3%6166
CALM Cal-Maine Foods Inc. Common Stock$63.83$7616% below50.9x2.4%2329
AGRO Adecoagro S.A. Common Shares$9.83$1947% below25.9x3.7%5065

Sector report card

Where BG ranks against its sector peers on each metric.

Computing percentiles…
  • Business Wire•Oct 1, 2026
    Bunge Schedules Third Quarter 2026 Earnings Release and Conference Call
  • Business Wire•Sep 1, 2026
    Bunge Announces the Sale of its Two Sugarcane Mills in Brazil
  • Business Wire•Aug 20, 2026
    Bunge to Present at Barclays Annual Global Consumer Conference
2 more press releases · full archive on Investor+.INVESTOR
30 filings of 40
April 2026
Apr 29
10-QQuarterly reportPeriod 2026-03-31
View on SEC →
Apr 29
8-KCurrent reportPeriod 2026-04-29
View on SEC →
Apr 10
ProxyProxy statementPeriod 2025-12-31
View on SEC →
27 more filings + AI summaries on Investor+.INVESTOR